Breast Cancer News
In this section, access cutting-edge metastatic breast cancer news on treatment updates, emerging therapies, study results and other medical and quality-of-life issues important to you.
SILVER SPRING, Md. (Reuters) - U.S. health advisers delivered a blow to Roche Holding on Wednesday, voting to reject the use of Roche Holding drug Avastin for breast cancer while the Swiss drugmaker conducts more studies.
FDA officials have invited the public to testify at a hearing that will argue the merits of bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer.
The National Comprehensive Cancer Network’s updated clinical practice guidelines for metastatic breast cancer retain bevacizumab as a treatment option and add two new therapies, the chemotherapy medicine eribulin and the RANKL inhibitor denosumab.
FDA has agreed to Genentech’s request to revisit the agency’s decision to withdraw bevacizumab (Avastin) as an approved treatment for HER2 negative metastatic breast cancer. A public hearing is scheduled for June 28-29, and the resultant ruling is final.
Roche/Genentech, maker of Avastin (bevacizumab), has requested a hearing before the U.S. Food and Drug Administration to appeal the agency’s December 2010 decision to withdraw approval of bevacizumab as a treatment for metastatic breast cancer.
CHICAGO (Reuters) - Women with advanced breast cancer who were treated with Roche's Avastin were more likely to develop heart failure than other women, according to an analysis released on Tuesday that raised more concerns about the already troubled drug.
Women with metastatic breast cancer share how they feel about FDA’s decision to rescind approval of bevacizumab (Avastin) as a treatment for metastatic breast cancer.
The Food and Drug Administration (FDA) has approved denosumab to help prevent bone damage in people with cancer that has spread to the bone tissue.
Living Beyond Breast Cancer Statement on FDA’s Decision to Remove Approval of Avastin for Metastatic Breast Cancer
The U.S. Food and Drug Administration (FDA) yesterday announced that it plans to begin the process necessary to withdraw approval of Avastin (bevacizumab) as a treatment for metastatic breast cancer. Living Beyond Breast Cancer (LBBC) encourages insurance carriers and the federal government to continue reimbursing payment for Avastin for women currently taking it who are responding to it. Additionally, we strongly encourage the manufacturer to continue its program to assist women in need who are taking Avastin and are responding.
FDA's announcement that it plans to withdraw approval of Avastin in metastatic breast cancer begins a review process that could last several months. Learn about the timeline for a decision, the impact on access and insurance coverage, and how to submit public comments to FDA.